Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03. | Neumora stock rating cut to Market Perform at William Blair | 4 | Investing.com | ||
10.03. | Neumora stock holds Buy rating and $18 target from H.C. Wainwright | 3 | Investing.com | ||
07.03. | Neumora cut to Hold at Stifel after J&J's VENTURA exit | 6 | Seeking Alpha | ||
07.03. | Guggenheim cuts Neumora Therapeutics stock rating to neutral | 5 | Investing.com | ||
NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
07.03. | Stifel cuts Neumora Therapeutics stock rating to hold | 5 | Investing.com | ||
04.03. | Neumora bids farewell to R&D head; Biohaven's 'one step forward, one step back' data | 10 | BioPharma Dive | ||
04.03. | Needham & Company LLC Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) | 4 | MarketBeat | ||
04.03. | HC Wainwright Issues Pessimistic Forecast for Neumora Therapeutics (NASDAQ:NMRA) Stock Price | 3 | MarketBeat | ||
04.03. | Neumora Therapeutics: Finanzielle Entwicklung und Marktchancen | 4 | IT BOLTWISE | ||
03.03. | Neumora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
03.03. | Guggenheim maintains buy on Neumora shares, target at $7 | 4 | Investing.com | ||
03.03. | Neumora halts trial of depression drug, rethinks 2 others to apply lessons from phase 3 failure | 3 | FierceBiotech | ||
03.03. | Stifel cuts Neumora Therapeutics target to $6, maintains Buy | 7 | Investing.com | ||
03.03. | Neumora Therapeutics, Inc. Q4 Loss Decreases, Beats Estimates | 7 | RTTNews | ||
03.03. | Neumora Therapeutics GAAP EPS of -$0.37 beats by $0.08 | 4 | Seeking Alpha | ||
03.03. | Neumora Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
03.03. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
24.02. | Mizuho cuts Neumora Therapeutics price target to $4 | 6 | Investing.com | ||
20.02. | Präsident von Neumora Therapeutics verkauft Aktien im Wert von 13.477 US-Dollar | 7 | Investing.com Deutsch | ||
20.02. | Finanzvorstand von Neumora Therapeutics verkauft Aktien im Wert von 14.347 US-Dollar | 4 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 83,95 | -4,11 % | Bayer, Vidac Pharma, BioNTech - Niederschläge und neue Maßstäbe | Glyphosat und kein Ende. Die Übernahme des US-amerikanischen Agrarunternehmens Monsanto durch Bayer im Jahr 2018 entwickelt sich weiterhin zum Milliardengrab, erneut entschied ein Gericht gegen die... ► Artikel lesen | |
CUREVAC | 2,576 | -7,14 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
AMGEN | 287,30 | +1,86 % | Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis | ||
NOVAVAX | 5,998 | -7,38 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
BIOGEN | 126,70 | -0,74 % | Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen | |
MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie
27.03.2025 / 14:01... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,420 | -5,00 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily
Results Expected in 2H25
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 6,596 | -11,30 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,036 | -3,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 0,880 | -0,79 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | +4,90 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 59,80 | -8,00 % | Sarepta downgraded at RBC Capital on gene therapy concerns | ||
EXELIXIS | 33,410 | -1,45 % | FDA approves Exelixis' Cabometyx to treat advanced neuroendocrine tumours | ||
VAXART | 0,360 | -7,93 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
TEMPUS AI | 48,380 | +1,90 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? |